Published in Gene on August 01, 2006
An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn (2010) 2.48
Genomic assessments of the frequent loss of heterozygosity region on 8p21.3-p22 in head and neck squamous cell carcinoma. Cancer Genet Cytogenet (2007) 1.19
8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosis. PLoS One (2009) 1.14
Ras-association domain family 1C protein promotes breast cancer cell migration and attenuates apoptosis. BMC Cancer (2010) 0.99
Transcriptional differences between normal and glioma-derived glial progenitor cells identify a core set of dysregulated genes. Cell Rep (2013) 0.93
Genomic characterization of the human mitochondrial tumor suppressor gene 1 (MTUS1): 5' cloning and preliminary analysis of the multiple gene promoters. BMC Res Notes (2009) 0.92
Angiotensin II type 2 receptors have a major somatodendritic distribution in vasopressin-containing neurons in the mouse hypothalamic paraventricular nucleus. Neuroscience (2009) 0.91
Down-regulation of tumor suppressor MTUS1/ATIP is associated with enhanced proliferation, poor differentiation and poor prognosis in oral tongue squamous cell carcinoma. Mol Oncol (2011) 0.91
Invading basement membrane matrix is sufficient for MDA-MB-231 breast cancer cells to develop a stable in vivo metastatic phenotype. PLoS One (2011) 0.90
Frequent loss of heterozygosity in two distinct regions, 8p23.1 and 8p22, in hepatocellular carcinoma. World J Gastroenterol (2007) 0.85
How does angiotensin AT(2) receptor activation help neuronal differentiation and improve neuronal pathological situations? Front Endocrinol (Lausanne) (2012) 0.85
Reduced expression of MTUS1 mRNA is correlated with poor prognosis in bladder cancer. Oncol Lett (2012) 0.84
The role of the basal stem cell of the human breast in normal development and cancer. Adv Exp Med Biol (2011) 0.81
Lipoprotein lipase as a candidate target for cancer prevention/therapy. Biochem Res Int (2011) 0.81
MTUS1/ATIP3a down-regulation is associated with enhanced migration, invasion and poor prognosis in salivary adenoid cystic carcinoma. BMC Cancer (2015) 0.79
Effect of angiotensin II type 2 receptor-interacting protein on adipose tissue function via modulation of macrophage polarization. PLoS One (2013) 0.79
Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective study. BMC Cancer (2014) 0.78
Microtubule associated tumor suppressor 1 deficient mice develop spontaneous heart hypertrophy and SLE-like lymphoproliferative disease. Int J Oncol (2011) 0.77
p53 regulates the expression of human angiotensin II AT(2) receptor interacting protein (ATIP1) gene. Oncol Lett (2011) 0.77
The Expression of MTUS1/ATIP and Its Major Isoforms, ATIP1 and ATIP3, in Human Prostate Cancer. Cancers (Basel) (2011) 0.75
Angiotensin II type 2 receptor-interacting protein 3a suppresses proliferation, migration and invasion in tongue squamous cell carcinoma via the extracellular signal-regulated kinase-Snai2 pathway. Oncol Lett (2015) 0.75
AT2 Receptor-Interacting Proteins ATIPs in the Brain. Int J Hypertens (2013) 0.75
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science (2003) 19.77
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet (1996) 6.43
Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst (1998) 6.06
Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J (2005) 5.46
Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res (1999) 4.74
Molecular characterization of the human beta 3-adrenergic receptor. Science (1989) 4.13
Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet (2000) 3.50
Disrupted in Schizophrenia 1 Interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia. Mol Psychiatry (2006) 3.33
Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer. Lancet (1992) 3.11
Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet (1996) 2.97
A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet (1998) 2.68
Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc Natl Acad Sci U S A (1986) 2.66
Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet (1998) 2.59
Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst (1994) 2.58
Novel approach to quantitative polymerase chain reaction using real-time detection: application to the detection of gene amplification in breast cancer. Int J Cancer (1998) 2.52
Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network. Ann Oncol (2013) 2.42
Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology (2000) 2.21
Reduction to homozygosity of genes on chromosome 11 in human breast neoplasia. Science (1987) 2.17
Tissue distribution of beta 3-adrenergic receptor mRNA in man. J Clin Invest (1993) 2.16
Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Genes Chromosomes Cancer (1998) 2.09
Presence of two members of c-erbA receptor gene family (c-erbA beta and c-erbA2) in smallest region of somatic homozygosity on chromosome 3p21-p25 in human breast carcinoma. J Natl Cancer Inst (1989) 2.09
Lymphocyte migration through brain endothelial cell monolayers involves signaling through endothelial ICAM-1 via a rho-dependent pathway. J Immunol (1999) 2.03
Time of onset of non-insulin-dependent diabetes mellitus and genetic variation in the beta 3-adrenergic-receptor gene. N Engl J Med (1995) 1.99
Identification of four novel human genes amplified and overexpressed in breast carcinoma and localized to the q11-q21.3 region of chromosome 17. Genomics (1995) 1.96
Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr Relat Cancer (2006) 1.96
ICAM-1-coupled cytoskeletal rearrangements and transendothelial lymphocyte migration involve intracellular calcium signaling in brain endothelial cell lines. J Immunol (2000) 1.92
Role of transforming growth factor beta type II receptor in hepatic fibrosis: studies of human chronic hepatitis C and experimental fibrosis in rats. Hepatology (1999) 1.90
Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med (1995) 1.88
Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet (1998) 1.88
Genetic alterations in breast cancer. Genes Chromosomes Cancer (1995) 1.86
Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry (1986) 1.84
Complete amino acid sequence and maturation of the mouse submaxillary gland renin precursor. Nature (1982) 1.83
Dopamine visualized in the basal ganglia of living man. Nature (1983) 1.82
Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. Cancer Res (1998) 1.80
Anti-alprenolol anti-idiotypic antibodies bind to beta-adrenergic receptors and modulate catecholamine-sensitive adenylate cyclase. Proc Natl Acad Sci U S A (1980) 1.80
A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans. Nat Genet (2001) 1.79
A refined molecular taxonomy of breast cancer. Oncogene (2011) 1.78
Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet (2005) 1.78
A rabbit with the allotypic phenotype: ala2a3 b4b5b6. J Immunol (1974) 1.77
Presence of an allelic EcoRI restriction fragment of the c-mos locus in leukocyte and tumor cell DNAs of breast cancer patients. Proc Natl Acad Sci U S A (1985) 1.77
Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet (2001) 1.77
The human beta 3-adrenoceptor: the search for a physiological function. Trends Pharmacol Sci (1994) 1.76
Chemokines control fat accumulation and leptin secretion by cultured human adipocytes. Mol Cell Endocrinol (2001) 1.75
Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem (1999) 1.74
Recurrent chromosomal abnormalities in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer (1997) 1.74
Natural history of multiple sclerosis in a population-based cohort. Eur J Neurol (2008) 1.73
Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res (2001) 1.72
Internalization of beta-adrenergic receptor in A431 cells involves non-coated vesicles. Eur J Cell Biol (1989) 1.71
Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome. J Med Genet (2001) 1.70
Somatic mutations and human breast cancer. A status report. Cancer (1992) 1.69
Molecular characterization of the mouse beta 3-adrenergic receptor: relationship with the atypical receptor of adipocytes. EMBO J (1991) 1.65
Predictors of unfavorable outcome in intracranial angioplasty and stenting in a single-center comparison: results from the Borgess Medical Center-Intracranial Revascularization Registry. AJNR Am J Neuroradiol (2011) 1.65
The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res (2000) 1.62
Structure of the gene for human beta 2-adrenergic receptor: expression and promoter characterization. Proc Natl Acad Sci U S A (1987) 1.62
Haplotype and phenotype analysis of nine recurrent BRCA2 mutations in 111 families: results of an international study. Am J Hum Genet (1998) 1.61
Toward a brain map of auditory hallucinations. Am J Psychiatry (1992) 1.59
Loss of heterozygosity and linkage analysis in breast carcinoma: indication for a putative third susceptibility gene on the short arm of chromosome 8. Oncogene (1995) 1.58
Epidemiological, clinical, paraclinical and molecular study of a cohort of 102 patients affected with autosomal recessive progressive cerebellar ataxia from Alsace, Eastern France: implications for clinical management. Neurogenetics (2009) 1.58
ICAM-1 signaling pathways associated with Rho activation in microvascular brain endothelial cells. J Immunol (1998) 1.56
Regulation of gamma-glutamyl transpeptidase and alkaline phosphatase activities in immortalized rat brain microvessel endothelial cells. J Cell Physiol (1994) 1.55
VEGF overexpression in clinically localized prostate tumors and neuropilin-1 overexpression in metastatic forms. Int J Cancer (2000) 1.54
Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res (2000) 1.53
Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet (2008) 1.53
An Alu-mediated 6-kb duplication in the BRCA1 gene: a new founder mutation? Am J Hum Genet (1999) 1.52
Denaturing high-performance liquid chromatography detects reliably BRCA1 and BRCA2 mutations. Genomics (1999) 1.52
Loss of a c-H-ras-1 allele and aggressive human primary breast carcinomas. Cancer Res (1986) 1.52
Comprehensive allelotyping of human hepatocellular carcinoma. Oncogene (1997) 1.52
High frequency of rare alleles of the human c-Ha-ras-1 proto-oncogene in breast cancer patients. J Natl Cancer Inst (1986) 1.52
Comprehensive screening for constitutional RB1 mutations by DHPLC and QMPSF. Hum Mutat (2004) 1.52
Somatic allelic deletion of nm23 in human cancer. Cancer Res (1991) 1.50
Intercellular adhesion molecule 1 activation induces tyrosine phosphorylation of the cytoskeleton-associated protein cortactin in brain microvessel endothelial cells. J Biol Chem (1994) 1.46
Imaging features of primary and recurrent esophageal cancer at FDG PET. Radiographics (2000) 1.46
Xenon-127, a comparison with xenon-133 for ventilation studies. J Nucl Med (1977) 1.46
Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer (2008) 1.45
Identification of CGA as a novel estrogen receptor-responsive gene in breast cancer: an outstanding candidate marker to predict the response to endocrine therapy. Cancer Res (2001) 1.45
Mapping of a functional autoimmune epitope on the beta 1-adrenergic receptor in patients with idiopathic dilated cardiomyopathy. J Clin Invest (1990) 1.44
Frequent alteration of the DF3 tumor-associated antigen gene in primary human breast carcinomas. Cancer Res (1989) 1.41
Overexpression of stathmin in breast carcinomas points out to highly proliferative tumours. Br J Cancer (2000) 1.39
Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res (1998) 1.39
Disclosure to the family of breast/ovarian cancer genetic test results: patient's willingness and associated factors. Am J Med Genet (2000) 1.36
Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene. J Med Genet (2008) 1.36
Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions. Cancer Res (1999) 1.36
Evidence for reversible microclustering of lentil lectin membrane receptors on HeLa cells. FEBS Lett (1980) 1.34
Epileptic seizures in nonembolic cerebral infarction. Arch Neurol (1967) 1.34
Two distinct regions involved in 1p deletion in human primary breast cancer. Cancer Res (1993) 1.33
Cancer risk in heterozygotes for ataxia-telangiectasia. Int J Cancer (2001) 1.32
Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J Neurochem (1998) 1.31
The human beta 3-adrenergic receptor is resistant to short term agonist-promoted desensitization. Mol Pharmacol (1993) 1.31
Breast cancer risk in ataxia telangiectasia (AT) heterozygotes: haplotype study in French AT families. Br J Cancer (1999) 1.30
Quantification of estrogen receptor alpha and beta expression in sporadic breast cancer. Oncogene (2001) 1.29
Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer. Cancer Res (2000) 1.29